Forecast

The analysts' average price target is €86.58 (+36.35%). The median is €86.58 (+36.35%).

Buy
  10
Hold
  2
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • RadNet beats Q2 forecasts and raises full-year guidance

    RadNet reported adjusted EPS of $0.29 for Q2 2026 on revenue of $622.7m, both well above consensus estimates, and posted an adjusted EBITDA quarterly record of $99.7m. Total revenue rose 25% year over year, driven by stronger demand for advanced imaging and a 56.5% increase in digital-health revenue; ARR nearly doubled to $105.5m. The company raised its full-year targets for imaging revenue, adjusted EBITDA and free cash flow. The stock rose about 6% in after-hours trading, while management highlighted accelerated adoption of AI solutions and continued wage-pressure and integration risks. » More on de.investing.com


  • RadNet secures $250 million loan and lowers interest costs

    RadNet has amended its existing credit agreement and taken on an additional $250 million loan, which is being combined with the existing facility (totaling $1.2087 billion) and matures on April 18, 2031. Quarterly principal payments will rise from $2.4 million to about $3.1 million. RadNet plans to use the funds for acquisitions, organic growth, healthcare partnerships and general corporate purposes. The interest rate has been cut by 0.25 percentage points (choice of Term SOFR plus 2.00% or an alternate base rate plus 1.00%), and the terms of the revolving credit line were also improved, strengthening the company’s financial flexibility with a cash position of $455 million as of March 31, 2026. » More on de.investing.com


  • DeepHealth (RadNet subsidiary) launches AI platform Reporting Pro for radiology reporting

    DeepHealth, a wholly owned subsidiary of RadNet, has made Reporting Pro commercially available — an AI-powered platform for creating radiology reports that combines speech recognition, clinical AI findings, measurements, generative AI assessments, and quality assurance in a single workflow. The solution incorporates both FDA-cleared and CE-marked AI tools, can integrate with existing PACS/RIS systems, and supports all imaging modalities. RadNet is rolling out Reporting Pro across its own network, has secured initial external customers, and plans to expand into additional countries by the end of the year. » More on de.investing.com


  • Moody's cuts rating of RadNet's senior secured bank credit facilities after $200m loan

    Moody’s downgraded RadNet’s senior secured bank credit facilities from Ba3 to B1; the Corporate Family Rating remains at B1 with a stable outlook. The downgrade follows the issuance of an additional $200 million senior loan to finance acquisitions and expansion, which raises pro forma leverage from about 4.5x to around 5.0x. Moody’s cites higher fixed costs and geographic concentration as pressure points, but highlights RadNet’s strong competitive position, revenue diversification and a pro forma liquidity position of more than $600 million, and expects leverage to decline over the next 12–18 months. » More on de.investing.com


  • RadNet beats revenue forecasts in Q1 2026, stock rises despite EPS miss

    RadNet reported Q1 2026 revenue of $575.63 million versus $557.64 million expected (+3.23% surprise) with EPS of $-0.28 (forecast -$0.15). Revenue rose 22.1% year over year, adjusted EBITDA increased 36.3%, and days sales outstanding (DSO) were 29.5 days. The stock climbed 8.95% in premarket trading to $63.40 as investors reacted positively to revenue growth, digital health initiatives and acquisition contributions. RadNet maintains an upbeat outlook with FY 2026 guidance of $0.63 EPS and expected revenues of $2.45 billion. » More on de.investing.com

Financials

In the last quarter, RadNet had revenue of €563.49m and net profit of €3.67m

(EUR) September 2026
YoY
Revenue 563.49m 26.47%
Gross profit 75.81m 22.74%
Net profit 3.67m 20.57%
EBITDA 84.05m 27.39%

Fundamentals

Metric Value
Market capitalization
€5bn
Number of shares
78.77m
52-week high/low
€78.23 - €46.31
Dividends No
Beta
1.40
P/E ratio
-242.22
PEG ratio
3.65
P/B ratio
4.84
P/S ratio
2.30

Company profile

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Name
RadNet
CEO
Howard G. Berger
Headquarters Los Angeles, ca
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
10/12/2021
Employees 9,060

Ticker symbols

Exchange Symbol
NASDAQ
RDNT
Frankfurt
PQIA.F
DĂĽsseldorf
PQIA.DU
SIX
PQIA.SW
🍪

Parqet  uses cookies. Learn more